PL3103453T3 - Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy - Google Patents

Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy

Info

Publication number
PL3103453T3
PL3103453T3 PL15746276T PL15746276T PL3103453T3 PL 3103453 T3 PL3103453 T3 PL 3103453T3 PL 15746276 T PL15746276 T PL 15746276T PL 15746276 T PL15746276 T PL 15746276T PL 3103453 T3 PL3103453 T3 PL 3103453T3
Authority
PL
Poland
Prior art keywords
active ingredient
medicinal composition
carboxamide compound
heterocyclic carboxamide
diamino heterocyclic
Prior art date
Application number
PL15746276T
Other languages
English (en)
Inventor
Tomohiro Eguchi
Masamichi Mori
Yoko Yamaki
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Publication of PL3103453T3 publication Critical patent/PL3103453T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
PL15746276T 2014-02-04 2015-02-03 Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy PL3103453T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014019226 2014-02-04
EP15746276.3A EP3103453B1 (en) 2014-02-04 2015-02-03 Medicinal composition comprising diamino heterocyclic carboxamide compound as active ingredient
PCT/JP2015/053018 WO2015119122A1 (ja) 2014-02-04 2015-02-03 ジアミノヘテロ環カルボキサミド化合物を有効成分とする医薬組成物

Publications (1)

Publication Number Publication Date
PL3103453T3 true PL3103453T3 (pl) 2020-06-29

Family

ID=53777926

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15746276T PL3103453T3 (pl) 2014-02-04 2015-02-03 Kompozycja lecznicza zawierająca jako składnik czynny heterocykliczny związek diaminokarboksyamidowy

Country Status (29)

Country Link
US (2) US11045468B2 (pl)
EP (1) EP3103453B1 (pl)
JP (1) JP6390626B2 (pl)
KR (1) KR102322338B1 (pl)
CN (3) CN116509866A (pl)
AU (1) AU2015215578B2 (pl)
BR (1) BR112016017897A8 (pl)
CA (1) CA2938818C (pl)
CY (1) CY1122968T1 (pl)
DK (1) DK3103453T3 (pl)
EA (1) EA033304B1 (pl)
ES (1) ES2788390T3 (pl)
HR (1) HRP20200662T1 (pl)
HU (1) HUE049437T2 (pl)
IL (1) IL247077B (pl)
LT (1) LT3103453T (pl)
ME (1) ME03775B (pl)
MX (1) MX363543B (pl)
MY (1) MY193536A (pl)
PH (1) PH12016501527B1 (pl)
PL (1) PL3103453T3 (pl)
PT (1) PT3103453T (pl)
RS (1) RS60150B1 (pl)
SG (1) SG11201606413RA (pl)
SI (1) SI3103453T1 (pl)
TW (1) TWI655945B (pl)
UA (1) UA120607C2 (pl)
WO (1) WO2015119122A1 (pl)
ZA (1) ZA201605379B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201606413RA (en) * 2014-02-04 2016-09-29 Astellas Pharma Inc Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
HRP20230253T1 (hr) * 2015-07-03 2023-04-28 Astellas Pharma Inc. Stabilna farmaceutska kompozicija za oralnu administraciju
JP6859954B2 (ja) * 2015-11-04 2021-04-14 アステラス製薬株式会社 ジアミノヘテロ環カルボキサミド化合物を有効成分とするがん免疫治療用、及び/又は、免疫活性化用医薬組成物
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2022220227A1 (ja) * 2021-04-14 2022-10-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピリドピリミジン化合物
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009102446A2 (en) * 2008-02-12 2009-08-20 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
AU2009226153B2 (en) 2008-03-19 2014-02-20 Chembridge Corporation Novel tyrosine kinase inhibitors
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
NO3009428T3 (pl) * 2009-05-08 2018-07-21
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
MX2014006087A (es) * 2011-11-21 2014-08-01 Immunogen Inc Metodo de tratamiento de tumores que son resistentes a terapias contra el receptor del factor de crecimiento epidermico (egfr) con agentes citotoxicos conjugados con anticuerpos dirigidos contra el receptor del factor de crecimiento epidermico.
UA113204C2 (xx) * 2012-04-02 2016-12-26 Селективна екстракція хлориду калію з відхідного шенітового розчину з використанням тартратної кислоти як безпечного м'якого екстрагента, придатного до рециркуляції
SI3447069T1 (sl) * 2012-11-21 2021-02-26 Janssen Biotech, Inc. Bispecifična protitelesa EGFR/C-MET
SG11201606413RA (en) * 2014-02-04 2016-09-29 Astellas Pharma Inc Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
WO2015127234A1 (en) 2014-02-20 2015-08-27 Board Of Regents, The University Of Texas System Use of ibrutinib to treat egfr mutant cancer
HRP20230253T1 (hr) * 2015-07-03 2023-04-28 Astellas Pharma Inc. Stabilna farmaceutska kompozicija za oralnu administraciju

Also Published As

Publication number Publication date
EP3103453B1 (en) 2020-04-01
CN113425727A (zh) 2021-09-24
KR20160110498A (ko) 2016-09-21
CA2938818A1 (en) 2015-08-13
EP3103453A4 (en) 2017-09-06
EP3103453A1 (en) 2016-12-14
MX2016010134A (es) 2016-10-07
EA033304B1 (ru) 2019-09-30
AU2015215578A2 (en) 2016-10-20
HRP20200662T1 (hr) 2020-10-02
IL247077A0 (en) 2016-09-29
JP6390626B2 (ja) 2018-09-19
IL247077B (en) 2020-08-31
PH12016501527A1 (en) 2017-02-06
CN116509866A (zh) 2023-08-01
US20210290618A1 (en) 2021-09-23
LT3103453T (lt) 2020-05-11
EA201691570A1 (ru) 2016-11-30
CN105939714A (zh) 2016-09-14
SG11201606413RA (en) 2016-09-29
ES2788390T3 (es) 2020-10-21
US20160339020A1 (en) 2016-11-24
MY193536A (en) 2022-10-18
US11045468B2 (en) 2021-06-29
NZ722750A (en) 2020-11-27
JPWO2015119122A1 (ja) 2017-03-23
BR112016017897A8 (pt) 2020-06-30
US11925638B2 (en) 2024-03-12
KR102322338B1 (ko) 2021-11-05
UA120607C2 (uk) 2020-01-10
PT3103453T (pt) 2020-05-06
WO2015119122A1 (ja) 2015-08-13
DK3103453T3 (da) 2020-04-20
HUE049437T2 (hu) 2020-09-28
CA2938818C (en) 2023-03-07
PH12016501527B1 (en) 2017-02-06
AU2015215578A1 (en) 2016-08-18
CY1122968T1 (el) 2021-10-29
RS60150B1 (sr) 2020-05-29
MX363543B (es) 2019-03-27
ZA201605379B (en) 2018-05-30
ME03775B (me) 2021-04-20
SI3103453T1 (sl) 2020-10-30
TWI655945B (zh) 2019-04-11
AU2015215578B2 (en) 2019-07-11
TW201613594A (en) 2016-04-16

Similar Documents

Publication Publication Date Title
HK1219432A1 (zh) 以嘧啶化合物爲有效成分的醫藥組合物
IL247062A0 (en) Heterocyclic compounds, their preparation and pharmaceutical preparations containing them
ZA201605379B (en) Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient
IL253538A0 (en) Heterocyclic compound and pharmaceutical compound containing it
IL248090A0 (en) Solid pharmaceutical preparations containing biopterin derivatives and their uses
EP2987786A4 (en) AMIDOPYRIDINOL DERIVATIVE OR PHARMACEUTICAL, SALT AND PHARMACEUTICAL COMPOSITION THEREFOR AS ACTIVE SUBSTANCE
PT3202759T (pt) Derivado de alfa-aminoamida e composição farmacêutica contendo o mesmo
IL304109A (en) Pharmaceutical preparations containing spinamide
HK1243927A1 (zh) 含有茶皂醇衍生物作爲活性成分的組合物
IL249010A0 (en) A pharmaceutical preparation containing a pyrazine carboxamide compound as an active ingredient
SG11201610636VA (en) Pharmaceutical preparation containing entecavir as active ingredient, and preparation method therefor
SG11201608845PA (en) Cosmetic composition containing mentha haplocalyx as active ingredient
EP3372231A4 (en) PHARMACEUTICAL COMPOSITION FOR ANTICANCER IMMUNOTHERAPY AND / OR FOR IMMUNOSTIMULATION, CONTAINING AS ACTIVE PRINCIPLE A HETEROCYCLIC DIAMINO CARBOXAMIDE COMPOUND
HUE053974T2 (hu) Szemészeti gyógyászati készítmény
IL252663A0 (en) A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient
EP3120848A4 (en) Therapeutic/preventive agent containing coumarin derivative as active ingredient
IL252664A0 (en) A pharmaceutical preparation containing an aromatic heterocyclic amide compound containing nitrogen as an active ingredient
HUE058886T2 (hu) Safinamidot tartalmazó gyógyászati készítmények